Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 28 · below the Ichimoku cloud · RSI 29 (oversold) · MACD below its signal
| 11.89 | 52-week high | +170.84% |
| 5.50 | Previous month high | +25.24% |
| 5.00 | Previous week high | +13.90% |
| 4.84 | R3 (classic) | +10.36% |
| 4.71 | R2 (classic) | +7.29% |
| 4.63 | Previous week low | +5.47% |
| 4.59 | Previous month low | +4.56% |
| 4.57 | Previous day high | +4.21% |
| 4.55 | R1 (classic) | +3.64% |
| 4.41 | Pivot | +0.57% |
| 4.39 | Price now | |
| 4.28 | Previous day low | −2.51% |
| 4.26 | S1 (classic) | −3.08% |
| 4.12 | S2 (classic) | −6.15% |
| 3.96 | S3 (classic) | −9.79% |
| 3.16 | 52-week low | −28.02% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $697.4K | 0.00% | 127.50K | +300% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CING trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 32.3 | 9.2 | -1.0 | -17.1 | -19.2 | 31.5 | -12.4 | 7.9 | -4.3 | -11.3 | +1.2% | ||
| 2025 | -7.7 | -9.5 | 4.4 | -2.1 | -6.9 | 3.8 | 27.3 | -23.0 | -1.8 | -3.3 | -1.6 | 16.4 | −12.0% |
| 2024 | -59.5 | -56.6 | -18.2 | -16.6 | -23.6 | -54.4 | 10.3 | 86.3 | -36.1 | -19.8 | 7.9 | 13.1 | −94.6% |
| 2023 | -3.9 | 86.3 | -45.0 | 9.6 | -15.7 | 2.2 | -44.0 | 23.2 | 10.4 | -39.4 | -27.1 | 22.0 | −61.7% |
| 2022 | -33.0 | -22.7 | 37.8 | -17.8 | -32.7 | 33.9 | -15.8 | 34.1 | -35.2 | 0.9 | -8.1 | 0.7 | −63.8% |
| 2021 | — |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 8, 2026 | Schaffer Shane J.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 6.9K | — |
| Mar 8, 2026 | Callahan Jennifer L.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 15.3K | — |
| Mar 8, 2026 | Silva Raul R.Officer | Stock Award(Grant) at price 0.00 per share. | 4.5K | — |
| Mar 8, 2026 | Brams MatthewOfficer | Stock Award(Grant) at price 0.00 per share. | 4.5K | — |
| Mar 8, 2026 | Patel Nilay Dahyabhai J.D.Officer | Stock Award(Grant) at price 0.00 per share. | 5.5K | — |
| Feb 12, 2026 | Hargroves Thomas JeffreyDirector | Purchase at price 5.04 per share. | 97.3K | $490.27K |
| Feb 5, 2026 | Werth Peter J.Director | Purchase at price 7.70 per share. | 19.5K | $149.80K |
| Feb 5, 2026 | Schaffer Shane J.Chief Executive Officer | Purchase at price 7.70 per share. | 6.8K | $52.43K |
| Feb 5, 2026 | Callahan Jennifer L.Chief Financial Officer | Purchase at price 7.70 per share. | 4.9K | $37.45K |
| Feb 5, 2026 | Brams MatthewOfficer | Purchase at price 7.70 per share. | 1.9K | $14.98K |
Buy / hold / sell counts
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.